

**DECLARATION FORM ON NOTHING TO DECLARE OR NOTHING NEW TO
DECLARE FOR USE IN THE INFORMATION EXCHANGE**

Measure	Nothing to declare	Nothing new to declare
A, part I	<input type="checkbox"/>	<input checked="" type="checkbox"/>
A, part 2 (i)	<input checked="" type="checkbox"/>	<input type="checkbox"/>
A, part 2 (ii)	<input checked="" type="checkbox"/>	<input type="checkbox"/>
A, part 2 (iii)	<input checked="" type="checkbox"/>	<input type="checkbox"/>
B (i)	<input type="checkbox"/>	<input type="checkbox"/>
B (ii)	<input checked="" type="checkbox"/>	<input type="checkbox"/>
C	<input checked="" type="checkbox"/>	<input type="checkbox"/>
D	<input checked="" type="checkbox"/>	<input type="checkbox"/>
E	<input type="checkbox"/>	<input checked="" type="checkbox"/>
F	<input checked="" type="checkbox"/>	<input type="checkbox"/>
G	<input type="checkbox"/>	<input checked="" type="checkbox"/>

(Please mark the appropriate box(es) for each measure, with a tick.)

Date: 2006-04-13

State Party to the Convention: Republic of Lithuania

CONFIDENCE BUILDING MEASURE A (Part I)

Form A, part 1

Exchange of data on research centres and laboratories¹

1. Name(s) of facility² Microbiological Laboratory of Vilnius Public Health Centre
2. Responsible public or private organization or company Ministry of Health
3. Location and postal address Žolyno str. 36
10210 Vilnius Lithuania
4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence
Ministry of Health
5. Number of maximum containment units³ within the research centre and/or laboratory, with an indication of their respective size (m²)
none
6. If no maximum containment unit, indicate highest level of protection
level 3
7. Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate
Public health purposes: diagnosis of infectious diseases such as Antrax, Cholera, Brucellosis, Listeriosis, Legionellosis, Botulism and others.

-
1. Name(s) of facility⁴ Lithuanian AIDS Center Laboratory
 2. Responsible public or private organization or company Ministry of Health

¹The containment units which are fixed patient treatment modules, integrated with laboratories, should be identified separately.

²For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark "Declared in accordance with Form A, part 2 (iii)".

³In accordance with the 1983 WHO Laboratory Biosafety Manual, or equivalent

⁴For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark "Declared in accordance with Form A, part 2 (iii)".

3. Location and postal address Vytenio str. 59/37
03209 Vilnius
Lithuania
4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence
Ministry of Health
5. Number of maximum containment units⁵ within the research centre and/or laboratory, with an indication of their respective size (m²)
None
6. If no maximum containment unit, indicate highest level of protection
Level 2 (size of containment - 52,39 m²)
7. Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate
Tested pathogens: HIV, HTLV, enteroviruses and poliomielytis, influenza and parainfluenza, measles, rubella, herpes infections, viral haemorrhagic fevers, parasitoses, tick born diseases, etc.

1. Name(s) of facility⁶ National Veterinary laboratory
2. Responsible public or private organization or company National Food and Veterinary Service
3. Location and postal address J.Kairiūkščio 10
08409 Vilnius Lithuania
4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence
National Food and Veterinary Service
5. Number of maximum containment units⁷ within the research centre and/or laboratory, with an indication of their respective size (m²)

⁵In accordance with the 1983 WHO Laboratory Biosafety Manual, or equivalent

⁶For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark "Declared in accordance with Form A, part 2 (ii)".

⁷In accordance with the 1983 WHO Laboratory Biosafety Manual, or equivalent

none

6. If no maximum containment unit, indicate highest level of protection

level 2

7. Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate

Rabies, Leptospyrosis, Anthrax, Tuberculosis, Brucelosis,
Salmonellosis and other viral and bacterial diseases of animals

Form A, part 2 (i)

National biological defence research and development programme Declaration

Is there a national programme to conduct biological defence research and development within the territory of the State Party, under its jurisdiction or control anywhere? Activities of such a programme would include prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research.

No

If the answer is Yes, complete Form A, part 2 (ii) which will provide a description of the programme.

Form A, part 2 (ii)

National biological defence research and development programme

NSTR

Form A, part 2 (iii)

National biological defence research and development programme

NSTR

Form B (i)

**Background information on outbreaks of reportable
infectious diseases**

This is in accordance with the WHO International Statistical Classification of Diseases and Related Health Problems, 10th Revision

Certain infectious and parasitic diseases in Lithuania for 2005

WHO Classification of Disease **Case per year**

A01(A01.0)	4
A01(A01.1-A 01.3)	0
A02(A02.0-A02.2, A02.8,A02.9)	2372
A03(A03.0-A03.9)	478
A04(A04.0-A04.8)	2006
A04(A04.0-A04.4)	165
A04(A04.3)	0
A04(A04.5)	694
A04(A04.6)	495
A04.9, A09	7890
A08(A08.0-A08.3,A08.5)	3802
A08(A08.0)	3032
A08(A08.1)	447
B	1
A08(A08.4)	826
A05(A05.0-A05.4, A05.8, A05.9)	846
A15(A15.0-A15.9), A19	1338
A17, A18	23
A21(A21.0-A21.3, A21.7-A21.9)	0
A22(A22.0-A22.2, A22.7-A22.9)	0
A23(A23.0-A23.3, A23.8,A23.9)	0
A27(A27.0,A27.8, A27.9)	7
A28.2	6

A32(A32.0,A32.1,A32.7-A32.9)	2
A33,A34,A35	4
A36(A36.0-A36.3, A36.8,A36.9)	0
A37(A37.0,A37.1, A37.8, A37.9)	64
A38	1196
A39(A39.0-A39.5, A39.8,A39.9)	81
G00(G00.0-G00.3, G00.8,G00.9)	69
A87(A87.0-A87.2, A87.8,A87.9)	190
A40.3, G00.1,J13,	36
A41.3, A49.2, G00.0, J14	22
A69.2	1161
A70	0
A56	563
A75(A75.0,A75.1)	0
A80(A80.0-A80.4,A80.9)	0
A82(A82.0, A82.1, A82.9)	0
A84(A84.0, A84.1, A84.9)	243
B	1
B01	16555
B05	1
B06	118
P35.0	0
B15-B19	300
B15	74
B16.2, B16.9	141
B17.1	68
B17.2	0
B16.0,B16.1, B17.0	0
B20, B21, B22, B24	4
B23	27
Z21	83
A51-A53	295

A50(A50.0-A50.7, A50.9)	2
A54	433
B26	101
B25(B25.0-B25.2, B25.8, B25.9)	12
P35.1	0
B27	265
J00-J06	592108
J10,J11	32809
A48.1, A48.2	1
A06(A06.0-A06.9), A07(A07.0, A07.3,A07.9)	83
A07.1	44
A07.2	0
B50,B51,B52,B53, B54	2
B58(B58.0-B58.3, B58.8,B58.9)	253
P37.1	1
B67(B67.0-B67.9)	15
B68(B68.0, B68.1, B68.9)	1
B	1
B69(B69.0,B69.1, B69.8, B69.9)	0
B70.0	0
B71.0	1
B75	13
B77(B77.0,B77.8, B77.9)	895
B79	39
B80	11456
B83.0	109
B55-B57,B65,B66, B72- B74,B78,B81	0
B85	1695
B86	4856
B35(B35.0-B35.6, B35.8,B35.9)	6624
A00(A00.0,A00.1,A00.9)	0
A20(A20.0-A20.3, A20.7- A20.9)	0

B04	0
B03	0
A78	0
A81.0	1
A83(A83.0-A83.6, A83.8, A83.9)	0
A90	0
A91	0
A92(A92.0-A92.4, A92.8,A92.9)	0
A95.0 (A95.0, A95.1,A95.9)	0
A96.2	0
A98 (98.3, 98.4, 98.5)	0
A98.3	0
A98.4	0
A98.5	0

Form B (ii)

Information on outbreaks of infectious diseases and similar occurrences, that seem to deviate from the normal pattern

NSTR

4. **CONFIDENCE-BUILDING MEASURE "C":**

- **Encouragement of publication of results and promotion of use of knowledge**
NSTR

Form D

Active promotion of contacts

1. Planned international conferences, symposia, seminars, and other similar forums for exchange
NSTR

2. Information regarding other opportunities

NSTR

Form E

Declaration of legislation, regulations and other measures

<u>Relating to</u>	<u>Legislation</u>	<u>Regulations</u>	<u>Other measures</u>	<u>Amended since last year</u>
(a) Development, production stockpiling, acquisition or retention of microbial or other biological agents, or toxins, weapons, equipment and means of delivery specified in Article I	YES	YES	YES	NO
(b) Exports of micro-organisms* and toxins	YES	YES	YES	NO
(c) Imports of micro-organisms* and toxins	YES	YES	YES	NO

* Micro-organisms pathogenic to man, animals and plants in accordance with the Convention.

Form F

Declaration of past activities in offensive and/or defensive biological research and development programmes

1. Date of entry into force of the Convention for the State party.
10 April 1997
2. Past offensive biological research and development programmes:
 - NO
 - Period(s) of activities
 - Summary of the research and development activities indicating whether work was performed concerning production, test and evaluation, weaponization, stockpiling of biological agents, the destruction programme of such agents and weapons, and other related research.
3. Past defensive biological research and development programmes:
 - NO
 - Period(s) of activities
 - Summary of the research and development activities indicating whether or not work was conducted in the following areas: prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination, and other related research, with location if possible.

Form G

Declaration of vaccine production facilities

No vaccines are produced in Lithuania